Key Takeaways
- Japan's economy grew at an annualized rate of 1.1% in the April-June quarter, supported by auto and semiconductor exports despite weak private consumption.
- AstraZeneca (AZN) is discontinuing its eVOLVE-Lung02 Phase III trial for volrustomig in lung cancer, though other Phase III trials for the drug remain on track.
- Chinese hedge funds are rotating out of Nvidia (NVDA) and U.S. hyperscalers, shifting capital toward hardware makers like Micron Technology (MU) and SanDisk ($WDC) in a maturing AI trade.
- Norway's trade surplus surged to 84.3 billion NOK in July, significantly exceeding the previous month's 61.9 billion NOK.
- Russian attacks on Ukrainian energy and port infrastructure intensified, with state-owned Naftogaz reporting 13 strikes over the past week and a Togo-flagged vessel damaged in Odesa.
Japan Economy Navigates Headwinds
Japan’s real gross domestic product (GDP) expanded at a seasonally adjusted rate of 0.3% in the second quarter of 2026, translating to an annualized growth rate of 1.1%. While the growth marks a third consecutive quarter of expansion, it fell short of analyst expectations as private spending dipped 1.2% amid rising energy costs driven by regional conflicts.
Exports remained a bright spot, growing 0.5% behind strong global demand for Japanese automobiles and semiconductors. Major manufacturers like Toyota Motor (TM) and Honda Motor (HMC) benefited from this trend, while the burgeoning AI sector continued to fuel demand for advanced chip components.
AstraZeneca Updates Volrustomig Pipeline
AstraZeneca (AZN) announced the discontinuation of its eVOLVE-Lung02 Phase III trial, which evaluated volrustomig in combination with chemotherapy for metastatic non-small cell lung cancer. The decision followed a recommendation from an Independent Data Monitoring Committee, which concluded the treatment was unlikely to meet its primary endpoints of progression-free or overall survival.
Despite the setback in lung cancer, the pharmaceutical giant emphasized that other Phase III volrustomig trials remain on track. These ongoing studies target various conditions, including cervical cancer, head and neck squamous cell carcinoma, and mesothelioma, as part of the company's broader oncology strategy.
Shift in Global AI Investment Strategy
Top-tier Chinese hedge funds, including Perseverance Asset Management and Greenwoods Asset Management, have significantly reduced their holdings in Nvidia (NVDA) and major U.S. hyperscalers. Filings indicate a 72% reduction in Nvidia positions by Perseverance, with capital being redeployed into hardware and memory specialists like Micron Technology (MU).
This rotation suggests the "AI trade" is entering a more selective phase, focusing on infrastructure providers and hardware makers rather than just software and platform giants. Market observers note that investors are becoming more demanding regarding the monetization of massive AI capital expenditures.
Geopolitical Tensions Impact Energy and Trade
In Eastern Europe, the state energy giant Naftogaz reported that Russian forces attacked its facilities 13 times over the past week, targeting production assets and drilling sites to disrupt winter heating preparations. Additionally, a Togo-flagged civilian vessel was damaged by an overnight strike at a port in Ukraine’s Odesa region, further threatening Black Sea maritime logistics.
Meanwhile, in Northern Europe, Norway reported a robust trade balance of 84.3 billion NOK for July, up from 61.9 billion NOK in June. In Sweden, the Origo Group Inflation Expectations Survey showed one-year expectations rising slightly to 1.8%, providing critical data for the Riksbank ahead of its upcoming interest rate decision.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.